IO Biotech Inc (IOBT) Financiero

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.